NEW YORK, Oct. 16 – Atugen, a Berlin-based genomics company, said Tuesday it had signed a target validation deal with AstraZeneca.

Under the terms of the deal, Atugen will use its GeneBloc antisense technology to validate targets of interest to the British pharmaceutical company. The companies previously completed a target evaluation deal that dates back to 1999.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Parabon NanoLabs is partnering with law enforcement to use genetic genealogy approaches to solve cold cases, Buzzfeed News reports.

A Columbia University-led team used emergency contact information from medical records to create family trees and estimate disease heritability.

In Science this week: ancient Southeast Asian genomes provide insight on human migration, and more.

NPR says a new report recommends that former research chimpanzees should be moved to retirement sanctuaries unless that move would shorten their lives.